A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Summary

A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.

Timeline

Start

2023-02-15

Primary completion

2023-11-21

Completion

2023-11-21

Outcome

Met primary endpoint

release “today announced positive top-line results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in patients with atopic dermatitis.” aldeyra.com ↗

Drugs

Indications